Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Hi Lending, :-) Nice surprise to hear from you! Unfortunately life events meant I took my eye off the ball at the completely wrong time, so I'm running at an overall loss at present. Fairly confident in my portfolio, so just a matter of patience I guess. Hope your investments have faired better? It's definitely been crazy, but as you say, `this too shall pass'!
Seeing LUCE and DARK at such bargain basement prices is making me itch to buy,however now I'm getting a decent cash interest rate, it seems prudent to wait until I can see a market turn ahead.
I've looked in on the DARK board a couple of times and still interested in buying back in at some point. Haven't got the patience to deal with certain characters at present, but I'll pop by to catch up with the nice sane posters like yourself sometime. All the best. :-)
There are some real bargains to be had while the market is this bearish, wish I'd saved more cash for buying a bigger holding here and getting my average down.
Jim, I've haven't heard about Vyjuvek from the contacts I have within the UK EB community, but then I've not been as involved since my family member passed on. Dystrophic EB sufferers already carry a high risk of developing cancer and my understanding is that gene therapy itself carries an enhanced risk, which is why my money was (literally) on Filsuvez.
However... Vyjuvek doesn't seem to be an insertional gene therapy so I'm wondering whether the risk has been deemed to be much lower with topical application? It's a fascinating area and thanks for the prompt as it's something I should really research further.
From my own perspective I can't see how the FDA would compare one against the other simply because of the difference in approach/risk.
Bermuda, that's a wonderful gesture and I very much share your hopes for swift Filsuvez approval and developments of other treatments for EB. Wishing the very best luck to you and Jim and to all remaining holders here going forward.
I've also reluctantly decided to cut my loss here and sold my holding. Having done a bit of research, I don't think the FDA extension necessarily signifies anything good or bad for Filsuvez, but having shouldered a loss elsewhere this week, I simply can't risk a heavier hit than I've already taken right now. All the best.
Watchman, agree, it's an incredibly difficult decision to make. Holding long-term was always my plan here, but in a way that was keeping me from making the right decision for me in the midst of crazy volatility. This experience has strongly reaffirmed keeping as diversified a portfolio as possible. I'm very lucky that my loss here has been cushioned by other holdings, at present, but definitely a wake up call to rebalance my portfolio towards staple holdings.
I still think the PH note was intended to be a self-fulfilling prophecy, it's inexcuseable to discount major income streams and misunderstand how the technology fits into the market, when evaluating a company! Unfortunately even that leads back to the fallout from Autonomy/HP and ML's involvement.
Charles, thank you. I'll still be swinging by to see how things are going, so no slacking on keeping it real round here. ;-) GL.
Lending, many thanks, much appreciate your kind words. I will definitely update the board on my geeky findings & thoughts on the tech and anything DARK related along the way. Or just generally stick my oar in. :-))
Lending, a belated, but sincere `thank you' for your detailed response. Apologies, I should have stated who I meant when I asked your opinion on KAL: https://forum.quidisq.com/t/darktrace-dark-buffettology-buying-at-the-ipo/337 Quite an interesting forum judging from what I've read so far and fairly civilised! I don't know enough about `Buffetology' the fund or the philosophy to draw any firm conclusions, however my investing style appears closely aligned to value/contrarian methodologies, so it's definitely an area for more research.
Your words on speculative stocks rang a timely bell for me and your thoughts on a shift into stocks with subscriptions/pricing power makes a lot of sense. The future of SaaS is looking strong and Adobe/Microsoft are both rock solid and well ahead of the pack. I may well follow a similar route - I also appreciate the tip about gold as a possible hedge as it was something I've been meaning to look into anyway.
I've sold my holding in DARK this morning, having re-evaluated my portfolio. It was a very difficult decision to take, not only because I've shouldered a loss in doing so, but also because I recognise it was something I should have done a lot earlier. Long-term, as you know, I believe the future of the company is exceptionally bright, and the contract news this morning only adds to that belief. The volatility, the ongoing ML fiasco, against a worrying economic background are however weighing too heavily on me. I'll likely look to buy back in at some point when things appear calmer all round. All the best and GLALTH.
Propinquity, I've emailed my broker to request my shares be deposited, quoting from the RNS to explain why. I couldn't find the forms that are supposed to accompany the circular, but presume our brokers can sort it from here. Fingers-crossed!
I agree totally, you've echoed my own thoughts. My own limited experience in holding overseas stocks has been difficult due to the exchange rate/tax, so not overly pleased by the timing. With no liquidity at all and looking at a loss if I sell, I'm resigned to going with the flow. Long-term I think it'll come good, but Amryt management haven't covered themselves in glory, presenting this to holders after the fact.
This is the third time I've agreed with you recently JIm. I may have to go and have a lie-down in a dark room! ;-)
Jim, I'm interested to hear your thoughts on the move, good or bad?
Jim, Bermuda & Propinquity, thank you for the positive feedback, it means a lot. Thanks too for the link to the stem cell research Bermuda, which I hadn't heard about. Although treatments like this and AP103 are at a very early stage of development, there's at least hope of alleviation ahead for sufferers.
Interesting news today. It's probably a good decision for the company, not so sure whether it's a good deal for us as holders, but hoping it means it's looking good for Filsuvez. Good luck all.
Lending, a very measured and sensible post imo. DARK ran a premier showcase at Gartner's US expo last week, so I'm more optimistic for a continuing upswing in sales growth, but your cautious realism seems wise.
Have you any thoughts on KAL's investment here? Been reading up a bit since you told me about the Buffettology factsheet.
Your previous response to Beryl gave me a lot of food for thought regarding my own portfolio strategy too - I read it belatedly so didn't get an opportunity to say thank you.
Charles, that's correct from a post I made last night, but you took it completely out of context by applying your own meaning to it! It wasn't a prediction, it's my personal belief this will recover over time which is why I preceded it with `I agree it will take patience' and `believe'. That's not in any sense`could it turn a corner today?' It clearly wasn't a PREDICTION about TODAY!
Hey Marna and Beryl, hope you're both okay. Totally agree with PussyG, the volatility cuts both ways. We're all in the red to an extent presently, but I have faith here based on the company, it's products and the growing market for them. The market is irrational and sentiment will turn positive again on good news. I agree it will take patience, but every reason to believe we'll turn the corner. :-)
Agreed and if further evidence is needed, similar just happened with THG: `Investment bank Numis reports itself to watchdog after retracting memo about THG 'irregularities' ': https://news.sky.com/story/investment-bank-numis-reports-itself-to-watchdog-after-retracting-memo-about-thg-irregularities-12470950 Possible court case in the offing too.
Candid & Jim, sorry for the late response and I very much hope you're right on the FDA decision Candid. A you said it's a treatment not a cure, but the effect of any beneficial treatment can make a lot of difference. As well as being invested here, I have direct experience of Dystrophic EB as family-carer to a sufferer for decades. We were also involved in the formation of the main charity, so I've done a lot of research and know/n other sufferers personally.
It's from that perspective I know anything beneficial to prevent infection spread is important. Pain for sufferers is constant with degrees of severity, however I emphasise the infection risk in particular because alongside the additional pain caused, it also ups the mortality risk over time. As a side-note the only pain-management available for severe EB sufferers is via drugs like Fentanyl which bring along their own terrible problems and mortality risk (as detailed in the US recently).
JimBeann, there are some things we can definitely agree on, you'll be surprised to hear I even upticked your reply on OO to Elrico's bizarre Greta rant. :-) I agree with Mark Summeray, there would be benefit in dressings being changed less frequently (it's often a traumatic and painful procedure), though because of the infection risk, they'd still need changing daily. It's terrible when they're kids, but the suffering can be even worse for those who do reach adulthood. :-(
I'm an LTH here, but as well as a good investment case, it's also my way of supporting Amryt in bringing treatments to a cause that's very special to me. GLALTH.
As things have turned out, you, Nidec and Bladerunner played it almost perfectly here Seaking. That you're looking to buy back speaks volumes. I remain a LTH as was always my strategy, but it's been a good lesson in tweaking my strategy. Running a loss isn't fun, but I have confidence thanks to the in-depth research. Not worth sharing much here while the kids are running amok.
Inflation certainly isn't helping, but it too will pass. I've also sold off profitable holdings that might be hit in order to buy them back cheaper. I agree, this is totally undervalued now imho. I've averaged down as much as my risk appetite will allow, so #patienthands. ;-)
It's AI emboldened, from my research. Uses recursive Bayesian estimation. https://www.youtube.com/watch?v=0lKHFJpaZvE
If you look at the background of the Executive Managment Team it's also clear what level of expertise we're talking about here. Definitely not `ai'.